Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2020-04-22 Regulatory Filings
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings
2020-04-22 English
FORM 8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is a notice from Nasdaq regarding the company's non-compliance with the minimum stockholders' equity requirement for continued listing, which is a delisting-related matter. The document discusses the notice received, the company's plan to regain compliance, and the potential consequences if the plan is not accepted. There are no financial statements or detailed financial analysis present, only an announcement of a regulatory event related to listing status. Therefore, this document fits the category of a Delisting Announcement (DLST). The document length is over 6,000 characters, so it is not a brief announcement of a report publication but a substantive regulatory filing about delisting. Hence, the classification is DLST with high confidence.
2020-04-21 English
FORM POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Form S-1 Registration Statement filed with the SEC. It relates to the registration of shares underlying previously issued warrants and references incorporation of financial statements from the Annual Report on Form 10-K. The document is a regulatory filing updating and supplementing information in a registration statement, not a financial report or earnings release. It is a formal SEC filing related to capital raising and securities registration, specifically a post-effective amendment to a registration statement under the Securities Act of 1933. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a proxy statement, but a substantive amendment to a registration statement.
2020-04-17 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 14, 2020, reporting an entry into a material definitive agreement related to litigation funding. It details the terms of the Litigation Funding Agreement and the related legal proceedings. The document does not contain financial statements or quarterly/annual financial results, nor is it a transcript, proxy, or governance report. It is a regulatory announcement of a material event (entry into a litigation funding agreement) rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2020-04-14 English
FORM 10-K
Annual Report FY 2019
2020-04-09 English
FORM NT 10-K
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, BioCardia, Inc., was unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, within the prescribed time period due to delays caused by the COVID-19 pandemic. The document explains the reasons for the delay and indicates that the Form 10-K will be filed shortly after the due date. There are no actual financial statements or substantive financial data included in this document; it is purely an announcement of a late filing of the 10-K report. According to the classification rules, such a notification is not the report itself but an announcement related to the report filing status. Therefore, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories and includes officer certifications, attestations, and notifications like this one.
2020-03-31 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.